Reviewing Coeptis Therapeutics (NASDAQ:COEP) and DBV Technologies (NASDAQ:DBVT)

Coeptis Therapeutics (NASDAQ:COEPGet Free Report) and DBV Technologies (NASDAQ:DBVTGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.93, meaning that its stock price is 193% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares Coeptis Therapeutics and DBV Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coeptis Therapeutics $80,000.00 150.61 -$21.27 million ($0.53) -0.61
DBV Technologies $15.73 million 6.07 -$72.73 million ($0.84) -1.18

Coeptis Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Coeptis Therapeutics and DBV Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics 0 0 1 0 3.00
DBV Technologies 1 0 2 0 2.33

Coeptis Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 824.21%. DBV Technologies has a consensus price target of $6.67, suggesting a potential upside of 573.40%. Given Coeptis Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Coeptis Therapeutics is more favorable than DBV Technologies.

Insider & Institutional Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Coeptis Therapeutics and DBV Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coeptis Therapeutics N/A -479.38% -226.57%
DBV Technologies -530.89% -56.76% -43.18%

Summary

Coeptis Therapeutics beats DBV Technologies on 8 of the 14 factors compared between the two stocks.

About Coeptis Therapeutics

(Get Free Report)

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About DBV Technologies

(Get Free Report)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.